Aranesp Oncology Costs: “Exorbitant” (J&J); “Very Competitive” (Amgen)
Executive Summary
An Aranesp (darbepoetin) dosing regimen in oncology using a "priming" dose followed by a reduced maintenance dose creates a cost of treatment comparable to Johnson & Johnson's Procrit (epoetin alfa), Amgen maintains
You may also be interested in...
J&J Wants Changes To Medicare OPPS Rule; Procrit Could Benefit
Johnson & Johnson is hoping for changes in the proposed 2003 Medicare Outpatient Prospective Payment System that would even out reimbursement differences between Procrit (epoetin) and Amgen's Aranesp (darbepoetin)
J&J Wants Changes To Medicare OPPS Rule; Procrit Could Benefit
Johnson & Johnson is hoping for changes in the proposed 2003 Medicare Outpatient Prospective Payment System that would even out reimbursement differences between Procrit (epoetin) and Amgen's Aranesp (darbepoetin)
Aranesp Oncology Label Includes Emphasis On Longer Half-Life Than Procrit
Aranesp labeling for chemotherapy-induced anemia includes increased emphasis on the product's less frequent dosing than epoetin alfa (J&J's Procrit)